Optimize your therapeutic protein expression with the GS Gene Expression System®
Combining our advanced proprietary technology with our unparalleled expertise, the GS® expression platform can help you optimize your therapeutic protein expression. With the ability to rapidly and reliably generate high-producing cell lines, we can support the optimal expression of monoclonal antibodies and next-generation biologics, helping reduce your time to market.
Access a range of mammalian protein expression technologies
Benefit from access to our proven and scalable CHO based gene expression system to create a diverse range of biologic drugs. As market demand continues to rise for more potent and effective therapeutics, drug developers are identifying novel disease targets and biological mechanisms for new medicines. As a result, biologic pipelines are developing from standard antibody formats to next-generation biologics.
Proprietary technology and expertise are at the core of our expression platforms. Combined with our experience, it makes us the ideal partner to provide you with a robust and versatile expression system to optimize your production.
Take our advanced technologies in your laboratory under a license or rely on Lonza to do it for you.
From our clients
This powerful GS platform enabled us to fast-track CMC development from stable cell line generation to non-GMP Tox material supply to GMP clinical manufacturing.
— Dr. Feng Hui, Chief Operation Officer, Junshi Biosciences, China. July 2020
I just wanted to send a specific note of thanks for your early support in getting us the Xceed system – it was truly a differentiator for the program.
— Prof. Trent Munro, Program Director, The University of Queensland, Australia. June 2020
Integrating GS piggyBac® transposon technology to GS Xceed® results in higher bsAb expression, and offers benefits for bioprocessing for low expressing proteins, helping to generate high performing pools.
— Dr. Jizu Yi, Senior Vice President, YZY Biopharma, China. June 2021
We have successfully expressed and produced a variety of recombinant bispecific antibodies and viral proteins by Lonza's GS Xceed expression system. The viral antigens expressed by the GS Xceed® system show superior immunogenicity and the glycosylation type covers the kinds of viral proteins already available quite well.
— Jian Kong, CEO, Luzhu Biotech. Apr 2022
... GSv9™ Media and Feeds resulted in ~50% more antibody production. Its preparation demonstrated to be less time-consuming and labor intensive. The GSv9™ Media demonstrated a higher potential for prolonging cell culture for additional day(s).
— Dr. Faraz Harsini, Scientist, Xbiotech Inc, USA. Sep 2020
..having access to the Lonza system during the pandemic really empowered our work. Lonza has spent years developing the GS SYSTEM to get it to where it is today, and the combination of the GS knockout cell line and cell culture platform result in a robust upstream platform. The GS XCEED expression system brought great benefits to our project because it allowed us to move fast – speed was clearly crucial at the start of a public health crisis.
— Prof. Trent Munro, Program Director, The University of Queensland, Australia. Dec 2021